Clinical Trial Update: Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating azacitidine (Vidaza) for patients with myelodysplastic syndrome or acute myeloid leukemia at impending hematologic relapse.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Technische Universität Dresden | Conditions: Acute Myelocytic Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED